Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Differential ligand binding/trafficking for distinct CTLA-4 fates: is it an expandable mechanism?

Cellular & Molecular Immunology volume 20, pages 1–2 (2023)Cite this article

Subjects

Autoimmunity and cancer progression occur as immune cells lose their ability to distinguish healthy self-cells or control the outgrowth of malignant cells. Immune dysfunction results from limited antigen recognition, immune suppression, or functional remodeling of immune cells [2]. The inflammatory properties of autoimmune diseases are similar to those of early-stage cancer but different from those of advanced cancer. Therefore, the incidence of various cancers is elevated in patients with preexisting autoimmune diseases [3].

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Kennedy A, Waters E, Rowshanravan B, et al. Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. Nat Immunol. 2022;23:1365–78.

    Article  CAS  Google Scholar 

  2. Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345–59.

    Article  CAS  Google Scholar 

  3. Elkoshi Z. Cancer and autoimmune diseases: a tale of two immunological opposites? Front Immunol. 2022;13:821598.

    Article  CAS  Google Scholar 

  4. Kim GR, Choi JM. Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) Signaling in T-cell biology and disease therapy. Mol Cells. 2022;45:513–21.

    Article  CAS  Google Scholar 

  5. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.

    Article  CAS  Google Scholar 

  6. Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood. 2016;128:1037–42.

    Article  CAS  Google Scholar 

  7. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–5.

    Article  CAS  Google Scholar 

  8. Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509–28.

    Article  CAS  Google Scholar 

  9. Sugiura D, Maruhashi T, Okazaki IM, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364:558–66.

    Article  CAS  Google Scholar 

  10. Zuidema A, Wang W, Sonnenberg A. Crosstalk between cell adhesion complexes in regulation of mechanotransduction. Bioessays. 2020;42:e2000119.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Ji Eon Kim, Eunmi Kim.

Authors and Affiliations

  1. Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea

    Ji Eon Kim, Eunmi Kim & Jung Weon Lee

Authors
  1. Ji Eon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eunmi Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jung Weon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jung Weon Lee.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, J.E., Kim, E. & Lee, J.W. Differential ligand binding/trafficking for distinct CTLA-4 fates: is it an expandable mechanism?. Cell Mol Immunol 20, 1–2 (2023). https://doi.org/10.1038/s41423-022-00945-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-022-00945-3

Search

Advanced search

Quick links